Sunday, September 13, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· June 12, 2026

LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)

View original at globenewswire.com
LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS) Company to be Renamed NOMAD Power Solutions • First-to-Market with the Mobile, Utility-Grade 1 MW BESS • Addressing a Multi-Hundred-Billion-Dollar Power Capacity Opportunity…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • NOMAD is engaged on more than 30 active utility, infrastructure and strategic customer opportunities across North America.

    60% confidence
  • NOMAD has built a proven operating platform and technology that directly addresses one of the most significant constraints facing economic growth today. This transaction positions the Company at the center of powerful long-term trends — artificial intelligence, electrification, grid modernization and industrial expansion.

    60% confidence
  • This transaction creates one of the first publicly traded companies singularly focused on solving one of the most significant constraints facing economic growth today — access to reliable electrical power.

    60% confidence
  • Management believes the structural permitting and deployment advantage of mobile BESS is one of the most underappreciated drivers of customer adoption and a defining competitive feature of the deployable BESS category.

    60% confidence
  • NOMAD's ability to deploy megawatt-scale storage anywhere in under an hour — without the siting delays, permitting burdens, or capital lock-up of traditional installations — is a genuine breakthrough.

    60% confidence
  • The acceleration in customer demand across utility, AI infrastructure and industrial markets confirms that deployable BESS is becoming an essential layer of the modern grid.

    60% confidence
  • NOMAD has built the only mobile, utility-grade BESS platform that meets the performance, safety and interconnection standards of investor-owned utilities, electric cooperatives, municipal utilities and large industrial energy users.

    60% confidence
  • Approximately 2.3 terawatts of generation and storage capacity remain in U.S. interconnection queues, and project development timelines have expanded from approximately two years historically to five to seven years or longer.

    60% confidence
  • Approximately 75% of NOMAD's sales activity is inbound.

    60% confidence
  • NOMAD's mobile BESS architecture is deployed as equipment rather than permanent infrastructure, generally bypassing land use entitlements, NEPA/CEQA environmental review, local moratoria and the multi-year interconnection queue.

    60% confidence
  • In New York State alone, 108 local jurisdictions have enacted moratoria or bans on permanent BESS, with approximately 1 GW of permanent battery storage sidelined under these restrictions.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Keeps Flowing as Enterprise Adoption and Government Contracts Validate the Bet
A late-August surge of nine-figure funding rounds (Socure, Stability AI, Generalist AI, Gatik, Regent Craft, Emerald AI, Owner) shows venture capital still pouring into AI infrastructure, identity/fintech, and autonomy, even as public-market sentiment stays jumpy — Palantir's stock fell 6% the same week it landed the Army's TITAN contract. UiPath's raised guidance and strong Q2 results, alongside efficiency breakthroughs like Multiverse Computing's model compression, point to real enterprise monetization catching up to the funding hype.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com